Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · October 06, 2023

Mechanisms of Benefits of SGLT2 Inhibitors in Patients With HFpEF

European Heart Journal

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Heart Journal
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Eur Heart J 2023 Sep 07;[EPub Ahead of Print], AK Pandey, DL Bhatt, A Pandey, N Marx, F Cosentino, A Pandey, S Verma

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading